Two independent multi‑omic reports tracked immune events after a gene‑edited pig kidney was transplanted into a brain‑dead human recipient and maintained for 61 days. Researchers performed dense sampling of tissue, blood and fluids and used transcriptomics, proteomics and single‑cell analyses to chart rejection dynamics and tolerance features. Teams led by Robert Montgomery and collaborators found rejection was driven by both allo‑antibodies and antigen‑specific T cells; crucially, investigators reversed rejection with a combination of approved immunomodulatory drugs targeting antibody and T‑cell pathways without permanent graft damage. The studies—published in Nature—provide day‑by‑day immune atlases that identify cell populations, complement activation and vascular injury signatures associated with graft failure and recovery. Clarification: xenotransplantation refers to transplanting organs between species; these multi‑omics datasets give the field mechanistic targets and candidate regimens to prevent or treat rejection in moving toward living human trials.